CPAP Intervention as an Add-On Treatment to Lipid-Lowering Medication in Coronary Artery Disease Patients with Obstructive Sleep Apnea in the RICCADSA Trial

Yeliz Celik, Baran Balcan, Yüksel Peker, Yeliz Celik, Baran Balcan, Yüksel Peker

Abstract

Dyslipidaemia is a well-known risk factor for coronary artery disease (CAD), and reducing lipid levels is essential for secondary prevention in management of these high-risk individuals. Dyslipidaemia is common also in patients with obstructive sleep apnea (OSA). Continuous positive airway pressure (CPAP) is the first line treatment of OSA. However, evidence of a possible lipid-lowering effect of CPAP in CAD patients with OSA is scarce. We addressed the effect of CPAP as an add-on treatment to lipid-lowering medication in a CAD cohort with concomitant OSA. This study was a secondary analysis of the RICCADSA trial (Trial Registry: ClinicalTrials.gov; No: NCT00519597), that was conducted in Sweden between 2005 and 2013. In total, 244 revascularized CAD patients with nonsleepy OSA (apnea-hypopnea index ≥ 15/h, Epworth Sleepiness Scale score < 10) were randomly assigned to CPAP or no-CPAP. Circulating triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) levels (all in mg/dL) were measured at baseline and 12 months after randomization. The desired TG levels were defined as circulating TG < 150 mg/dL, and LDL levels were targeted as <70 mg/dL according to the recent guidelines of the European Cardiology Society and the European Atherosclerosis Society. A total of 196 patients with available blood samples at baseline and 12-month follow-up were included (94 randomized to CPAP, 102 to no-CPAP). We found no significant between-group differences in circulating levels of TG, TC, HDL and LDL at baseline and after 12 months as well as in the amount of change from baseline. However, there was a significant decline regarding the proportion of patients with the desired TG levels from 87.2% to 77.2% in the CPAP group (p = 0.022), whereas there was an increase from 84.3% to 88.2% in the no-CPAP group (n.s.). The desired LDL levels remained low after 12 months in both groups (15.1% vs. 17.2% in CPAP group, and 20.8% vs. 18.8% in no-CPAP group; n.s.). In a multiple linear regression model, the increase in the TG levels was predicted by the increase in body-mass-index (β = 4.1; 95% confidence interval (1.0-7.1); p = 0.009) adjusted for age, sex and CPAP usage (hours/night). CPAP had no lipid-lowering effect in this revascularized cohort with OSA. An increase in body-mass-index predicted the increase in TG levels after 12 months, suggesting that lifestyle modifications should be given priority in adults with CAD and OSA, regardless of CPAP treatment.

Keywords: CPAP; coronary artery disease; dyslipidaemia; obstructive sleep apnea; randomized controlled trial.

Conflict of interest statement

Yüksel Peker received institutional grants from ResMed for the main RICCADSA trial. Yeliz Celik and Baran Balcan report no conflict of interest.

Figures

Figure 1
Figure 1
Consort flow chart of the study population.
Figure 2
Figure 2
Distribution of the circulating lipid levels at baseline and after 12 months in patients in the CPAP and no-CPAP groups.
Figure 3
Figure 3
Proportion of participants with the desired triglyceride and low-density lipoprotein levels at baseline and after 12 months.
Figure 4
Figure 4
Multiple linear regression line for the association between change in body-mass-index and change in circulating triglyceride levels after 12 months.

References

    1. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2019;41:111–188. doi: 10.1093/eurheartj/ehz455.
    1. Navar-Boggan A.M., Peterson E.D., D’Agostino S.R.B., Neely B., Sniderman A.D., Pencina M.J. Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. Circulation. 2015;131:451–458. doi: 10.1161/CIRCULATIONAHA.114.012477.
    1. Young T., Palta M., Dempsey J., Skatrud J., Weber S., Badr S. The Occurrence of Sleep-Disordered Breathing among Middle-Aged Adults. N. Engl. J. Med. 1993;328:1230–1235. doi: 10.1056/NEJM199304293281704.
    1. Peppard P.E., Young T., Barnet J.H., Palta M., Hagen E.W., Hla K.M. Increased Prevalence of Sleep-Disordered Breathing in Adults. Am. J. Epidemiol. 2013;177:1006–1014. doi: 10.1093/aje/kws342.
    1. Gunduz C., Basoglu O.K., Kvamme J.A., Verbraecken J., Anttalainen U., Marrone O., Steiropoulos P., Roisman G., Joppa P., Hein H., et al. Long-term positive airway pressure therapy is associated with reduced total cholesterol levels in patients with obstructive sleep apnea: Data from the European Sleep Apnea Database (ESADA) Sleep Med. 2020;75:201–209. doi: 10.1016/j.sleep.2020.02.023.
    1. Trzepizur W., Le Vaillant M., Meslier N., Pigeanne T., Masson P., Humeau M.P., Bizieux-Thaminy A., Goupil F., Chollet S., Ducluzeau P.H., et al. Independent Association Between Nocturnal Intermittent Hypoxemia and Metabolic Dyslipidemia. Chest. 2013;143:1584–1589. doi: 10.1378/chest.12-1652.
    1. Chen L., Einbinder E., Zhang Q., Hasday J., Balke C.W., Scharf S.M. Oxidative Stress and Left Ventricular Function with Chronic Intermittent Hypoxia in Rats. Am. J. Respir. Crit. Care Med. 2005;172:915–920. doi: 10.1164/rccm.200504-560OC.
    1. Mesarwi O.A., Loomba R., Malhotra A. Obstructive Sleep Apnea, Hypoxia, and Nonalcoholic Fatty Liver Disease. Am. J. Respir. Crit. Care Med. 2019;199:830–841. doi: 10.1164/rccm.201806-1109TR.
    1. Toyama Y., Chin K., Chihara Y., Takegami M., Takahashi K.-I., Sumi K., Nakamura T., Nakayama-Ashida Y., Minami I., Horita S., et al. Association Between Sleep Apnea, Sleep Duration, and Serum Lipid Profile in an Urban, Male, Working Population in Japan. Chest. 2013;143:720–728. doi: 10.1378/chest.12-0338.
    1. Chopra S., Rathore A., Younas H., Pham L.V., Gu C., Beselman A., Kim I.-Y., Wolfe R.R., Perin J., Polotsky V.Y., et al. Obstructive Sleep Apnea Dynamically Increases Nocturnal Plasma Free Fatty Acids, Glucose, and Cortisol During Sleep. J. Clin. Endocrinol. Metab. 2017;102:3172–3181. doi: 10.1210/jc.2017-00619.
    1. Borovac J.A., Dogas Z., Supe-Domic D., Galic T., Bozic J. Catestatin serum levels are increased in male patients with obstructive sleep apnea. Sleep Breath. 2019;23:473–481. doi: 10.1007/s11325-018-1703-x.
    1. Marshall N.S., Wong K.K., Cullen S.R., Knuiman M.W., Grunstein R.R. Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the Busselton Health Study cohort. J. Clin. Sleep Med. 2014;10:355–362. doi: 10.5664/jcsm.3600.
    1. Javaheri S., Martinez-García M.A., Campos-Rodriguez F., Muriel A., Peker Y. Continuous Positive Airway Pressure Adherence for Prevention of Major Adverse Cerebrovascular and Cardiovascular Events in Obstructive Sleep Apnea. Am. J. Respir. Crit. Care Med. 2020;201:607–610. doi: 10.1164/rccm.201908-1593LE.
    1. Dodds S., Williams L.J., Roguski A., Vennelle M., Douglas N.J., Kotoulas S.-C., Riha R.L. Mortality and morbidity in obstructive sleep apnoea–hypopnoea syndrome: Results from a 30-year prospective cohort study. ERJ Open Res. 2020;6:00057-2020. doi: 10.1183/23120541.00057-2020.
    1. Xu H., Yi H., Guan J., Yin S. Effect of continuous positive airway pressure on lipid profile in patients with obstructive sleep apnea syndrome: A meta-analysis of randomized controlled trials. Atherosclerosis. 2014;234:446–453. doi: 10.1016/j.atherosclerosis.2014.03.034.
    1. Lin M.-T., Lin H.-H., Lee P.-L., Weng P.-H., Lee C.-C., Lai T.-C., Liu W., Chen C.-L. Beneficial effect of continuous positive airway pressure on lipid profiles in obstructive sleep apnea: A meta-analysis. Sleep Breath. 2015;19:809–817. doi: 10.1007/s11325-014-1082-x.
    1. Huang Z., Liu Z., Zhao Z., Zhao Q., Luo Q., Tang Y. Effects of Continuous Positive Airway Pressure on Lipidaemia and High-sensitivity C-reactive Protein Levels in Non-obese Patients with Coronary Artery Disease and Obstructive Sleep Apnoea. Hear. Lung Circ. 2016;25:576–583. doi: 10.1016/j.hlc.2015.10.021.
    1. Peker Y., Glantz H., Thunström E., Kallryd A., Herlitz J., Ejdebäck J. Rationale and design of the Randomized Intervention with CPAP in Coronary Artery Disease and Sleep Apnoea–RICCADSA trial. Scand. Cardiovasc. J. 2009;43:24–31. doi: 10.1080/14017430802276106.
    1. Peker Y., Glantz H., Eulenburg C., Wegscheider K., Herlitz J., Thunström E. Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial. Am. J. Respir. Crit. Care Med. 2016;194:613–620. doi: 10.1164/rccm.201601-0088OC.
    1. Quan S.F., Gillin J.C., Littner M.R., Shepard J.W. Sleep-related breathing disorders in adults: Recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999;22:667–689.
    1. Johns M.W. A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale. Sleep. 1991;14:540–545. doi: 10.1093/sleep/14.6.540.
    1. World Health Organization Obesity: Overview. [(accessed on 3 January 2022)]. Available online: .
    1. Coughlin S.R., Mawdsley L., Mugarza J.A., Wilding J.P.H., Calverley P.M.A. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur. Respir. J. 2007;29:720–727. doi: 10.1183/09031936.00043306.
    1. Drager L.F., Bortolotto L.A., Figueiredo A.C., Krieger E.M., Lorenzi-Filho G. Effects of Continuous Positive Airway Pressure on Early Signs of Atherosclerosis in Obstructive Sleep Apnea. Am. J. Respir. Crit. Care Med. 2007;176:706–712. doi: 10.1164/rccm.200703-500OC.
    1. Robinson G.V., Pepperell J.C.T., Segal H.C., Davies R.J.O., Stradling J.R. Circulating cardiovascular risk factors in obstructive sleep apnoea: Data from randomised controlled trials. Thorax. 2004;59:777–782. doi: 10.1136/thx.2003.018739.
    1. Comondore V.R., Cheema R., Fox J., Butt A., Mancini G.B.J., Fleetham J.A., Ryan C.F., Chan S., Ayas N.T. The Impact of CPAP on Cardiovascular Biomarkers in Minimally Symptomatic Patients with Obstructive Sleep Apnea: A Pilot Feasibility Randomized Crossover Trial. Lung. 2009;187:17–22. doi: 10.1007/s00408-008-9115-5.
    1. Chirinos J.A., Gurubhagavatula I., Teff K., Rader D.J., Wadden T.A., Townsend R., Foster G.D., Maislin G., Saif H., Broderick P., et al. CPAP, Weight Loss, or Both for Obstructive Sleep Apnea. N. Engl. J. Med. 2014;370:2265–2275. doi: 10.1056/NEJMoa1306187.
    1. Phillips C.L., Yee B.J., Marshall N.S., Liu P.Y., Sullivan D.R., Grunstein R.R. Continuous positive airway pressure reduces postprandial lipidemia in obstructive sleep apnea: A randomized, placebo-controlled crossover trial. Am. J. Respir. Crit. Care Med. 2011;184:355–361. doi: 10.1164/rccm.201102-0316OC.
    1. Adedayo A.M., Olafiranye O., Smith D., Hill A., Zizi F., Brown C., Jean-Louis G. Obstructive sleep apnea and dyslipidemia: Evidence and underlying mechanism. Sleep Breath. 2014;18:13–18. doi: 10.1007/s11325-012-0760-9.
    1. Lafontan M., Langin D. Lipolysis and lipid mobilization in human adipose tissue. Prog. Lipid Res. 2009;48:275–297. doi: 10.1016/j.plipres.2009.05.001.
    1. Trammell R.A., Verhulst S., Toth L.A. Effects of Sleep Fragmentation on Sleep and Markers of Inflammation in Mice. Comp. Med. 2014;64:13–24.
    1. Martínez-Cerón E., Casitas R., Galera R., Sánchez-Sánchez B., Zamarrón E., Garcia-Sanchez A., Jaureguizar A., Cubillos-Zapata C., Garcia-Rio F. Contribution of sleep characteristics to the association between obstructive sleep apnea and dyslipidemia. Sleep Med. 2021;84:63–72. doi: 10.1016/j.sleep.2021.05.012.
    1. Bonsignore M.R., Borel A.-L., Machan E., Grunstein R. Sleep apnoea and metabolic dysfunction. Eur. Respir. Rev. 2013;22:353–364. doi: 10.1183/09059180.00003413.
    1. Binar M., Akçam M.T., Karakoc O., Sagkan R.I., Musabak U.H., Gerek M. A new surgical technique versus an old marker: Can expansion sphincter pharyngoplasty reduce C-reactive protein levels in patients with obstructive sleep apnea? Eur. Arch. Oto-Rhino-Laryngol. 2017;274:829–836. doi: 10.1007/s00405-016-4290-0.
    1. Iannella G., Lechien J.R., Perrone T., Meccariello G., Cammaroto G., Cannavicci A., Burgio L., Maniaci A., Cocuzza S., Di Luca M., et al. Barbed reposition pharyngoplasty (BRP) in obstructive sleep apnea treatment: State of the art. Am. J. Otolaryngol. 2022;43:103197. doi: 10.1016/j.amjoto.2021.103197.
    1. Wise M.S. Objective measures of sleepiness and wakefulness: Application to the real world? J. Clin. Neurophysiol. 2006;23:39–49. doi: 10.1097/01.wnp.0000190416.62482.42.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel